BPC-157 oral vs SubQ — any noticeable difference in gut healing research?

Been looking at the literature on oral BPC-157 vs subcutaneous administration for gut-related research. Several studies suggest oral bioavailability is surprisingly decent for a peptide this size. Curious if anyone has seen comparative data or anecdotal reports from research contexts.

The Sikiric 2018 paper mentions systemic effects from oral administration, but the dosing protocols differ significantly. Would love to hear thoughts from anyone who has reviewed both routes.